| Market Capitalization (Millions $) |
12,938 |
| Shares
Outstanding (Millions) |
194 |
| Employees |
3,221 |
| Revenues (TTM) (Millions $) |
3,407 |
| Net Income (TTM) (Millions $) |
73 |
| Cash Flow (TTM) (Millions $) |
1,859 |
| Capital Exp. (TTM) (Millions $) |
132 |
Business Description
BioMarin Pharmaceutical Inc. is a biotechnology company that develops and commercializes innovative therapies for people with rare genetic diseases. The company was founded in 1997 in California, and has since grown to become a global leader in the development of targeted therapies. BioMarin's mission is to deliver new treatments that can help people with rare diseases live longer, healthier lives.
BioMarin focuses on developing treatments for rare genetic diseases that are caused by the absence or malfunction of a single protein. These diseases often manifest in childhood and can have a devastating impact on patients and their families. In many cases, there are no approved treatments available, leaving patients with few options.
BioMarin's research and development efforts are focused on four core therapeutic areas: metabolic disorders, hemophilia, lysosomal storage disorders, and oncology. In metabolic disorders, the company is developing treatments for phenylketonuria (PKU) and achondroplasia, a form of dwarfism. In hemophilia, BioMarin is developing gene therapies that aim to cure patients of the disease. In lysosomal storage disorders, the company has developed treatments for Fabry disease and Pompe disease, and is working on treatments for mucopolysaccharidosis types I, II, and III. In oncology, BioMarin is developing a cancer immunotherapy that targets solid tumors.
BioMarin's flagship product is Palynziq, a treatment for PKU that was approved by the FDA in 2018. The company also markets Kuvan, Naglazyme, Vimizim, and Brineura, which are treatments for various rare diseases. BioMarin is committed to developing treatments that are safe and effective, and that can improve the lives of patients with rare genetic diseases.
BioMarin is headquartered in San Rafael, California, and has operations in the United States, Europe, Latin America, and Asia. The company has an experienced management team, and a strong financial position that allows it to invest in research and development. BioMarin is committed to working closely with patients, families, and advocacy groups to ensure that its treatments meet the needs of the rare disease community.
Company Address: 770 Lindaro Street San Rafael 94901 CA
Company Phone Number: 506-6700 Stock Exchange / Ticker: NASDAQ BMRN
|
3.85% 
176.26 %